Virtually all tumors are genetically heterogeneous, containing subclonal populations of cells that are defined by distinct mutations 1 . Subclones can have unique phenotypes that influence disease progression 2 , but these phenotypes are difficult to characterize: subclones usually cannot be physically purified, and bulk gene expression measurements obscure interclonal differences. Single-cell RNA-sequencing has revealed transcriptional heterogeneity within a variety of tumor types, but it is unclear how this expression heterogeneity relates to subclonal genetic events -for example, whether particular expression clusters correspond to mutationally defined subclones 3, 4, 5, [6] [7] [8] [9] . To address this question, we developed an approach that integrates enhanced whole genome sequencing (eWGS) with the 10x Genomics Chromium Single Cell 5'
intratumoral expression heterogeneity, to identify expression signatures associated with subclonal mutations, and to find cell surface markers that could be used to purify subclones for further study. The data also revealed transcriptional heterogeneity that occurred independently of subclonal mutations, suggesting that additional factors drive epigenetic heterogeneity. This integrative approach for connecting genotype to phenotype in AML cells is broadly applicable for analysis of any sample that is phenotypically and genetically heterogeneous.
Main
Four cases of de novo AML and one of secondary AML were selected for study (clinical details in https://github.com/genome/scrna_mutations). eWGS (Fig. 1a) showed that these cases were genetically representative of AML, containing on average 26 mutations in wellestablished driver genes (e.g. DNMT3A, FLT3, NPM1, TP53, NRAS, IDH1, CEBPA), and representative clonal architecture, with at least one detectable subclone per case (Table 1,   Supplementary Table 1) 10 . Bulk RNA-sequencing revealed that on average, fewer than half of the mutations detected by eWGS were expressed (Table 1) .
High-depth sequencing of duplicate scRNA-seq libraries (Table 1 ) generated using the 5' (v1) and 3' (v2) 10x Genomics Chromium Single Cell Gene Expression workflows yielded consistent low-level coverage at least 10 kbp from the 5' and 3' ends of the average transcript (Fig. 1b) . For the average gene assayed using the 5' kit, at least 2.5% of the unique sequenced transcripts mapped to any given base up to 10 kbp away from the 5' transcription start site of the gene. Moreover, the same transcripts had highly correlated coverage patterns in single cell and bulk RNA-seq data (Fig. 1c) .
We identified mutation-containing reads and cells by extracting mutant and wild-type Unique Molecular Indices (UMIs) and cell barcodes corresponding to each variant position in the eWGS data (https://github.com/genome/scrna_mutations). A cell was labeled "mutant" if it contained at least one variant-containing read, and "wild-type" if only wild-type reads were detected. Due to low expression and allele dropout, mutations were not detectable in all AML cells; further, "wildtype" cells may contain undetected heterozygous mutations. Most cells with detected somatic mutations contained one mutation, with one read mapping to the variant position ( Supplementary Fig. 1 ). Single nucleotide variants (SNVs), insertions and deletions (indels, including FLT3-ITD and NPMc), and one gene fusion (NUP98-NSD1) were detectable in the single-cell data. We detected an average of 49 mutant cells per variant (range: 1-3944).
Founding clone mutations, subclonal mutations, and putative driver mutations were detectable in dozens to thousands of cells in each case (Table 1, Supplementary Table 1) . Previously, somatic variant detection from scRNA-seq data involved full-length cDNAs from small numbers of cells 5, 11 . Sensitivity of mutation detection was comparable in single cell and bulk RNA-seq data: on average, a slightly higher fraction of known mutations were detected in the scRNA-seq data (Table 1 , Fig. 1d , Supplementary Discussion).
We next sought to interpret the mutation data in the context of expression heterogeneity, which we summarized in each case using principal component analysis (Methods Table 2 ). This suggested that the distribution of cell types within the bone marrow samples of AML patients is one major source of expression heterogeneity.
To investigate sample composition in a more granular and unsupervised manner, we identified the nearest hematopoietic lineage of each cell by matching it to the most similar lineage-specific expression profile in the DMAP database 12 ( Fig. 2c, Fig. 3 ). The inferred sample composition varied widely among subjects, particularly with respect to the fraction of lineage- which usually have few copy number alterations 3, 4, 8, 10, 13, 14 .
We therefore combined single-cell mutation data with expression-based clustering and lineage inference to distinguish AML cells from non-AML clusters. Using the bone marrow sample from 809653 (which contained many non-AML cells, according to morphology and flow cytometry) we overlaid mutation data on the t-SNE plots by highlighting mutant cells (Fig. 2e-g ).
A germline SNP in the BAG1 gene served as a positive control, marking SNP-containing cells in all expression clusters (Fig. 2h) Fig. 2c ). In the other 4 cases, somatic mutations were also concentrated in specific cell clusters, suggesting that they represented AML cells (Fig. 3) . This approach may miss small clusters with mutant cells, and rare AML cells that co-cluster with cells of different lineages. Overall, combining expression and mutation data delineated clusters of AML cells more comprehensively than either method alone, and allowed us to identify abnormallydifferentiated AML cells ("lineage infidelity").
By combining lineage inference with single-cell mutation identification, we estimated the extent of differentiation of each tumor. Our conclusions were supported by flow cytometry and morphology, but provided more insight into the differentiation state of AML cells in individual samples (Fig. 2, Fig. 3 ). In two cases (809653, 782328), a considerable fraction of the mutant cells had expression signatures consistent with differentiated cells: erythrocytes and monocytes in 809653 (Fig. 2c) , and monocytes and NK-T cells in 782328 (Fig. 3d) . Likewise, 548327
contained mutant cells that co-clustered with wild-type B-and T-cells, suggesting that some AML cells display lineage infidelity (Fig. 3b) . Thus, this integrative genomic approach validates the concept that AML cells can have a variety of abnormal expression signatures, corresponding to different lineages and states of differentiation.
We next investigated the extent to which transcriptional heterogeneity was explained by mutational heterogeneity in each case. A subclonal mutation that drives an expression signature should be restricted in expression space. In contrast, a founding or subclonal mutation not associated with an expression signature should be present throughout expression space.
Furthermore, this should not be dependent on restricted expression of the mutant gene. To this end, we highlighted mutant cells on the t-SNE plot of each sample, and identified mutations that are nonuniformly distributed, even after controlling for that gene's expression (Fig. 2e-g, Fig. 3 , Supplementary Fig. 7 ). The results reveal that the relationship between expression heterogeneity and mutational heterogeneity is case-and mutation-dependent.
Two cases, 721214 and 508084, contained subclonal mutations with nonuniform distributions (Fig 3a,c) . Based on eWGS, 721214 contained a subclone defined by GATA2
R361C
.
In the scRNA-seq data, cells expressing GATA2 R361C were predominantly restricted to one side of the t-SNE plot, suggesting that AML cells containing this mutation have a unique expression signature ( Fig. 3a) . We characterized this signature using multiple regression, and orthogonally confirmed its existence using flow cytometry and PCR (Methods, Supplementary Methods, Supplementary Discussion, Supplementary Fig. 8 ). Two cases (809653 ( Fig. 2f-g ) and 782328
( Fig. 3d) ) exhibited complex mutation-associated expression profiles, and a third, 548327 ( Fig.   3b ), showed expression heterogeneity in the absence of discernable genetic heterogeneity (Supplementary Discussion).
The ability to map mutations in hundreds to thousands of individual cells also facilitates more conservative, direct analyses of intratumoral expression heterogeneity, using only cells that express a confirmed somatic mutation. We performed dimensionality reduction and graphbased clustering using these mutationally-defined AML cells, and selected genes with the most variable expression patterns ( Supplementary Fig. 9 ). We averaged expression of these genes within each cluster, and hierarchically clustered the results ( Supplementary Fig. 10 ). All samples showed intercellular heterogeneity in the expression of cell cycle genes (as expected) and genes that function in the immune system, especially the MHC Class II genes and/or CD74. All but one case (782328) showed intercellular variability in expression of TP53-interacting genes 15 .
Three cases (508084, 548327, 721214) showed intercellular heterogeneity in genes that interact with the vascular cell adhesion gene VCAM1, and three (721214, 782328, 809653)
showed heterogeneous expression of myeloid differentiation genes. There were also casespecific signatures, such as "response to reactive oxygen species" in 721214 15 . Notably, the Integrating approaches that link genetic and transcriptomic information in single cells has important implications for the study of heterogeneous cell populations. By combining eWGS and scRNA-seq data, we have shown that we can distinguish between tumor and non-tumor cells, identify tumor cells displaying lineage infidelity, more comprehensively evaluate the differentiation state of individual tumor samples, derive mutation-associated expression signatures, study transcriptional heterogeneity within confirmed tumor cells, and identify cellsurface markers that can be used to isolate specific cells for downstream studies. Further, the approach described here should be applicable--without additional modifications or customization--to virtually any tumor type.
Methods

Enhanced whole genome sequencing (eWGS), germline SNP detection, and somatic variant detection
For each case, we performed enhanced whole genome sequencing (eWGS) on bone marrow and matched normal tissue to identify germline and somatic variants. Libraries were captured using an IDT exome reagent enhanced with AML recurrently mutated genes 16 , then combined with WGS libraries and sequenced on an Illumina HiSeq4000, as described previously 17 . Germline mutations were called using GATK HaplotypeCaller v3.5 18 (parametersstand_emit_conf 10 -stand_call_conf 30) and filtered using recommended parameters (--filterExpression "QD < 2.0 || FS > 60.0 || MQ < 40.0 || MQRankSum < -12.5 || ReadPosRankSum < -8.0"). Somatic mutations (SNVs, indels, and copy number alterations)
were detected using an ensemble mutation calling approach, with detailed protocols as previously published 19 . Somatic structural variants were detected using Manta v0.29 20 .
Bulk RNA-sequencing RNA libraries were prepared using the TruSeq stranded kit, sequenced on the Illumina
HiSeq platform, and aligned as described previously 19 . Expression quantification was performed using Kallisto 0.43.1 21 and transcripts from ensembl version 74.
Single-cell RNA-sequencing sample preparation, data generation, and coverage analysis Flow sorting for live cells. Cryovials of AML cells were thawed as follows: While 9 ml of Fetal Bovine Serum (FBS) was allowed to come to ~24℃, AML cryovials were removed from liquid nitrogen, and warmed in a 37℃ water bath until cells began to thaw. After 1 minute, 1 ml of room temperature FBS was added to the warming cryovial with a P1000 pipet tip and allowed to mix with thawing cells. The freshly added FBS was removed from the cell pellet and transferred back to the FBS stock. This process was repeated 3-4 times until all cells from the cryovial could be poured directly into the FBS stock. The empty cryovial was rinsed once more with the FBS mixture. Cells were then pelleted by centrifugation at 300 G for 5 minutes and resuspended in Phosphate Buffered Saline (PBS) at a concentration of 1x10 6 cell/ml in 1x PBS. Cells were then pipetted through a 70 µm filter into a 5 ml tube for sorting. Cells were then stained with 1 µl 7-AAD per 1 ml of cells for 30 minutes at 4℃. Briefly, between 14,000-21,000 live cells were loaded onto the Chromium controller in an effort to recover between 10,000-15,000 cells for library preparation and sequencing. Gel beads were prepared according to standard manufacturer's protocols. Oil partitions of a single-cell + oligo coated gel beads (GEMs) were captured and reverse transcription was performed, resulting in cDNA tagged with a cell barcode and unique molecular index (UMI). Next, GEMs were broken and cDNA was amplified and quantified using an Agilent Bioanalyzer High Sensitivity chip (Agilent Technologies).
To prepare the final libraries, amplified cDNA was enzymatically fragmented, end-repaired, and polyA tagged. Fragments were then size selected using SPRIselect magnetic beads Evaluating transcript coverage as a function of distance from transcription start and stop points. Transcript alignment, counting, and inter-library normalization were performed using the Cell Ranger pipeline (10x Genomics, default settings, Version 2.1.1, GRCh38 reference) 22 . For the genes TP53, NPM1, GATA2, and DNMT3A, the depth at each transcript was evaluated using both scRNA-seq data as well as bulk RNA-seq data. For each gene, a canonical isoform was chosen by consulting the APPRIS database 23 (ENST00000445888.6, ENST00000296930.9, ENST00000341105.6 and ENST00000264709.7 respectively). For the scRNA-seq data, the number of unique barcode/UMI pairs was counted at each position. For the bulk RNA-seq data, the tool bamCoverage 24 was used to generate a wiggle file over the transcript at 1bp bin size. The resulting tracks were visualized using the UCSC Genome The plot was also truncated to 10,000bp to avoid edge effects related to the transcript selection process. Coverage plots were generated using the Gviz 26 and BiomaRt 27 R packages, versions
and 2.34.2 respectively. For each locus, both coding and non-coding exonic nucleotides
were considered at a 1bp bin size. Gene region tracks were retrieved directly from Ensembl v93. scRNA total read coverage was generated using bamCoverage, part of the deepTools package 24 , and scRNA cell barcode coverage can be found at https://github.com/genome/scrna_mutations.
Copy Number analysis.
Gene expression matrices were analyzed with the CONICSmat package for R 28 . The default filtering and normalization procedures were followed, as outlined in , appended it to the reference, and realigned the scRNA data. Barcodes from reads uniquely aligning to the mutant FLT3 sequence were then extracted. Similarly, the NUP98-NSD1 fusion in 508084 was detected by appending the fusion transcript to the input GTF file, then using kallisto 21 and its companion tool, pizzly, to identify fusion-supporting transcripts.
By assaying the positions of known somatic mutations in samples that did not harbor those mutations, we found that the false positive rate (the rate at which wild-type UMIs are called mutant) is site-specific, and at most 0.39% (Supplementary Table 4 ). For most SNVs, the vast majority of cells had at most one unique read at the variant position, but SNVs in several highly expressed, high-coverage genes (U2AF1, NPM1, SRSF2, NRAS) were more likely to have multiple reads per cell ( Supplementary Fig. 2a) . We then recorded which cells had wild-type or mutant sequence at that position. After using SciClone 29 to assign each somatic variant to a subclone, we assigned mutation-containing cells ("mutant cells") to their corresponding subclones. Cell-variant assignment can also be performed in an automated manner using the VarTrix tool (https://github.com/10xgenomics/vartrix).
Single-cell RNA-seq expression analysis and mutation integration. Transcript alignment, counting, and inter-library normalization were performed using the Cell Ranger pipeline (10x Genomics, default settings, Version 2.1.1). Using the Seurat R package 30 , cells that contained fewer than 10 expressed genes, more than 50% ribosomal transcripts, or more than 10% mitochondrial transcripts were removed. Genes that were expressed in fewer than 3 cells were also removed. For each cell, expression of each gene was normalized to the sequencing depth of the cell, scaled to a constant depth (10,000), and log-transformed. Variable genes were selected (x.low.cutoff = 0.0125, x.high.cutoff=5, y.cutoff=0.5, default settings otherwise).
Principal component analysis was performed on the variable genes, and the optimal number of principal components (PCs) for each sample was chosen using a combination of elbow plots, jackstraw resampling, and PC expression heatmaps (508084: 6, 548327: 8, 721214: 5, 782328:
7, 809653: 6, 809653 AML cells: 6). PCs were used for dimensionality reduction if they explained at least 2% of the variance; were statistically significant according to jackstraw resampling; exhibited consistent expression variation in heatmaps; and were not composed entirely of ribosomal, mitochondrial, or immune genes. Dimensionality reduction and visualization were performed with the t-SNE algorithm (Seurat implementation) using the PCs selected above. Unsupervised graph-based clustering of cells was performed using the indicated PCs, with resolution = 0.7. Cell cycle phase was determined using methodology provided in Seurat, based on relative expression of phase-specific genes 3 . The distribution of mutations on the t-SNE plot was robust to filtering for mitochondrial and ribosomal transcripts, the number of PCs used, the clustering resolution, and normalization for cell cycle phase. The mutation distribution was also robust to the particular implementation of the t-SNE algorithm, with the Seurat and Cell Ranger implementations giving consistent results. To assess the relationship between mutation distribution and expression of the mutated gene, we colored each cluster in each t-SNE plot according to the expression-normalized mutant cell fraction (mutant cell fraction divided by the average expression of the mutant gene in that cluster).
Mutation-expressing cells were analyzed in isolation using analogous methods, with the exception that fewer PCs were required to capture the variability in the data (508084: 4, 548327:
3, 721214: 6, 782328: 7, 809653: 6).
Expression heatmaps. An expression heatmap was generated for each sample by selecting the top 10 genes in each of the top 20 PCs, and averaging the expression of each gene in each cluster. To connect heterogeneity to the graph-based clusters, and to examine relationships among clusters, we averaged expression within each cluster, and hierarchically clustered the results. For the analogous analysis performed on mutant cells in isolation, we used the top 20
genes from each of the top n PCs, where n was chosen separately for each sample to minimize noise (508084: 4, 548327: 3, 721214: 6, 782328: 7, 809653: 6).
Lineage inference and AML cell identification. Cell-type inference was performed in an unsupervised, marker-free manner by training a nearest-neighbor algorithm on expression data from the DMAP database 12 , using Spearman correlation as the distance metric. Using this approach, cells that co-cluster by graph-based clustering tend to have the same inferred lineage and express the corresponding cell-type markers (when known). In the case of AML cells, the assigned lineage represents the normal lineage to which the AML cell is most transcriptionally similar. 
